^
    Back
    Association details:
    Biomarker:ICOS overexpression
    Cancer:Melanoma
    Drug Class:PD1 inhibitor +
    CTLA4 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Biomark Res
    Title:

    ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade

    Published date:
    06/01/2023
    Excerpt:
    High ICOS mRNA expression was identified as a surrogate for enriched immune cell infiltration and was associated with favorable overall survival (OS) in non-ICB-treated patients and predicted response and a prolonged progression-free survival (PFS) following ICB therapy initiation. ICOS hypomethylation, however, significantly correlated with poor OS in non-ICB patients but predicted higher response and prolonged PFS and OS in ICB-treated patients.
    DOI:
    10.1186/s40364-023-00508-2